Dezerv

Fund Overview

Fund Size

Fund Size

₹113 Cr

Expense Ratio

Expense Ratio

0.60%

ISIN

ISIN

INF03VN01886

Minimum SIP

Minimum SIP

₹500

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

06 Feb 2024

About this fund

This fund has been in existence for 3 months and 14 days, having been launched on 06-Feb-24.
As of 17-May-24, it has a Net Asset Value (NAV) of ₹10.21, Assets Under Management (AUM) of 112.60 Crores, and an expense ratio of 0.6%.
  • WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 2.15% since inception.
  • The fund's asset allocation comprises around 96.51% in equities, 0.00% in debts, and 3.49% in cash & cash equivalents.
  • You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

+2.15%

(Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity108.66 Cr96.51%
Others3.93 Cr3.49%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity12.78 Cr11.35%
Cipla LtdEquity10.23 Cr9.09%
Torrent Pharmaceuticals LtdEquity6.52 Cr5.79%
Zydus Lifesciences LtdEquity6.02 Cr5.35%
Mankind Pharma LtdEquity4.7 Cr4.17%
Max Healthcare Institute Ltd Ordinary SharesEquity4.29 Cr3.81%
Abbott India LtdEquity3.79 Cr3.36%
J.B. Chemicals & Pharmaceuticals LtdEquity3.7 Cr3.29%
Krishna Institute of Medical Sciences LtdEquity3.44 Cr3.05%
Ajanta Pharma LtdEquity3.42 Cr3.04%
Rainbow Childrens Medicare LtdEquity3.17 Cr2.82%
Poly Medicure LtdEquity3.15 Cr2.80%
Vijaya Diagnostic Centre LtdEquity3.13 Cr2.78%
Neuland Laboratories LimitedEquity3.11 Cr2.77%
Global Health LtdEquity3.05 Cr2.71%
Divi's Laboratories LtdEquity3.01 Cr2.68%
Glenmark Pharmaceuticals LtdEquity2.79 Cr2.48%
Piramal Pharma LtdEquity2.69 Cr2.39%
Clearing Corporation Of India LtdCash - Repurchase Agreement2.65 Cr2.36%
Aurobindo Pharma LtdEquity2.63 Cr2.34%
Aster DM Healthcare Ltd Ordinary SharesEquity2.59 Cr2.30%
Shilpa Medicare LtdEquity2.54 Cr2.25%
Laurus Labs LtdEquity2.35 Cr2.09%
Alembic Pharmaceuticals LtdEquity2.18 Cr1.93%
Jupiter Life Line Hospitals LtdEquity2.06 Cr1.83%
Fine Organic Industries Ltd Ordinary SharesEquity2.04 Cr1.81%
Glenmark Life Sciences LtdEquity1.63 Cr1.44%
Innova Captab LtdEquity1.55 Cr1.38%
Ami Organics LtdEquity1.34 Cr1.19%
Eris Lifesciences Ltd Registered ShsEquity1.31 Cr1.16%
Gufic Biosciences LtdEquity1.18 Cr1.05%
RPG Life Sciences LtdEquity1.15 Cr1.02%
Medi Assist Healthcare Services LtdEquity1.13 Cr1.00%
Net Receivables / (Payables)Cash0.53 Cr0.47%
182 DTB 30052024Bond - Gov't/Treasury0.5 Cr0.44%
364 DTB 23052024Bond - Gov't/Treasury0.25 Cr0.22%

Allocation By Market Cap (Equity)

Large Cap Stocks

33.08%

Mid Cap Stocks

18.77%

Small Cap Stocks

41.89%

Allocation By Credit Quality (Debt)

AAA

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare102.17 Cr90.74%
Basic Materials3.38 Cr3.00%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

14.57%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.69

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.16

Higher the better

Fund Managers

Piyush Baranwal

Piyush Baranwal

Since February 2024

Ramesh Mantri

Ramesh Mantri

Since February 2024

DP

Dheeresh Pathak

Since February 2024

NS

Naitik Shah

Since April 2024

Additional Scheme Detailsas of 30th April 2024

ISININF03VN01886Expense Ratio0.60%Exit Load1.00%Fund Size₹113 CrAge06 Feb 2024Lumpsum Minimum₹500Fund StatusOpen Ended Investment CompanyBenchmarkS&P BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹13.07 Cr54.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.0%1.0%₹694.50 Cr57.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹694.50 Cr55.3%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹36.50 Cr52.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹161.86 Cr48.4%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹161.86 Cr45.4%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2236.01 Cr52.1%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2236.01 Cr49.9%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹639.49 Cr53.9%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹16.41 Cr51.7%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, as of 17-May-2024, is ₹10.21.
The fund's allocation of assets is distributed as 96.51% in equities, 0.00% in bonds, and 3.49% in cash and cash equivalents.
The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Direct Growth are:-
  1. Piyush Baranwal
  2. Ramesh Mantri
  3. Dheeresh Pathak
  4. Naitik Shah